http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Insu Baek,Yu-Ji Lee,Soo Jin Park,박종상,Dae Joong Kim 대한화학회 2010 Bulletin of the Korean Chemical Society Vol.31 No.2
Hemodialysis vascular access dysfunction (HVAD) due to the aggressive development of venous neointimal hyperplasia remains a major complication for patients with synthetic arteriovenous grafts. Paclitaxel-coated expanded polytetrafluoroethylene (ePTFE) grafts effectively prevent neointimal yperplasia and stenosis. However, perigraft inflammation or edema can be another complication of ePTFE grafts, preventing early cannulation. Three different types of ePTFE grafts, including grafts without paclitaxel coating (control group, n = 12), grafts with paclitaxel coating at a dose density of 0.61 ug/mm2 (low concentration group, n = 12), and grafts with paclitaxel oating at a dose density of 1.15 ug/mm2 (high concentration group, n = 12) were placed in the backs of 12 rabbits, simultaneously. Six rabbits were euthanized after one week and the remaining six were euthanized two weeks after implantation. Perigraft inflammation, graft wall inflammation, stromal cell proliferation, blood vessel formation, tissue necrosis and edema were analyzed for the grafts in each animal. Inflammation surrounding the paclitaxel-coated grafts was significantly reduced compared to the control group. Stromal cell layers were detected at the interface between the graft and the surrounding tissue in the control group, infiltrated into the graft interstices, and differentiated into myofibroblasts for graft healing. Paclitaxel-coated grafts inhibited stromal cell proliferation and infiltration into the graft wall. Tissue necrosis and edema were not detected in either of the paclitaxel-coated graft groups.
Baek, Insu,Cho, AJin,Hwang, Jinsun,Kim, Heasun,Park, Jong-Sang,Kim, Dae Joong Korean Chemical Society 2013 Bulletin of the Korean Chemical Society Vol.34 No.6
Neointimal hyperplasia causes vascular access dysfunction in hemodialysis patients with synthetic arteriovenous (AV) grafts. Several studies have reported that paclitaxel- or sirolimus-eluting AV grafts inhibit neointimal hyperplasia and display lower rates of stenosis compared with control grafts. However, there have been few comparative studies of the efficacy of paclitaxel- and sirolimus-eluting grafts. We compared the neointimal hyperplasia of paclitaxel- and sirolimus-eluting grafts. AV grafts were implanted laterally between the common carotid artery and the external jugular vein in 12 female Landrace pigs. The animals were sacrificed six weeks after surgery. The neointimal hyperplasia at the anastomosis sites of the grafts was quantified using the ratio of the intragraft hyperplasia to the graft area (H/G ratio) at the graft-vessel interface. The area of intimal hyperplasia at the venous (paclitaxel 1.06 [0.72-1.56] vs sirolimus 2.40 [1.72-3.0] $mm^2$, P = 0.04) and arterial anastomosis sites (paclitaxel 0.93 [0.57-1.48] vs sirolimus 2.40 [1.72-3.0] $mm^2$, P = 0.04) was significantly different between the two groups. However, the H/G ratios for the venous anastomosis site (paclitaxel 0.25 (0.17-0.38) vs sirolimus 0.38 (0.2-0.66), P = 0.4) and the arterial anastomosis site (paclitaxel 0.19 (0.08-0.39) vs sirolimus 0.41 (0.34-0.50), P = 0.1) did not differ significantly between the groups. In conclusion, there was no significant difference in the inhibition of neointimal hyperplasia by sirolimus- and paclitaxel-eluting AV grafts.
Insu Baek,AJin Cho,Jinsun Hwang,김혜선,박종상,김대중 대한화학회 2013 Bulletin of the Korean Chemical Society Vol.34 No.6
Neointimal hyperplasia causes vascular access dysfunction in hemodialysis patients with synthetic arteriovenous (AV) grafts. Several studies have reported that paclitaxel- or sirolimus-eluting AV grafts inhibit neointimal hyperplasia and display lower rates of stenosis compared with control grafts. However, there have been few comparative studies of the efficacy of paclitaxel- and sirolimus-eluting grafts. We compared the neointimal hyperplasia of paclitaxel- and sirolimus-eluting grafts. AV grafts were implanted laterally between the common carotid artery and the external jugular vein in 12 female Landrace pigs. The animals were sacrificed six weeks after surgery. The neointimal hyperplasia at the anastomosis sites of the grafts was quantified using the ratio of the intragraft hyperplasia to the graft area (H/G ratio) at the graft–vessel interface. The area of intimal hyperplasia at the venous (paclitaxel 1.06 [0.72-1.56] vs sirolimus 2.40 [1.72-3.0] mm2, P = 0.04) and arterial anastomosis sites (paclitaxel 0.93 [0.57-1.48] vs sirolimus 2.40 [1.72-3.0] mm2, P = 0.04) was significantly different between the two groups. However, the H/G ratios for the venous anastomosis site (paclitaxel 0.25 (0.17-0.38) vs sirolimus 0.38 (0.2-0.66), P = 0.4) and the arterial anastomosis site (paclitaxel 0.19 (0.08-0.39) vs sirolimus 0.41 (0.34-0.50), P = 0.1) did not differ significantly between the groups. In conclusion, there was no significant difference in the inhibition of neointimal hyperplasia by sirolimus- and paclitaxel-eluting AV grafts.
NCM 조성비에 따른 파우치 셀의 EIS 기반 등가 회로 모델 파라미터 비교 분석
백인수(Insu Baek),이평연(Pyeongyeon Lee),김종훈(Jonghoon Kim) 전력전자학회 2021 전력전자학술대회 논문집 Vol.2021 No.7
리튬 니켈 코발트 망간 산화물(LiNiCoMnO<sub>2</sub>; NCM)은 우수한 에너지 밀도 특성으로 고용량 배터리 셀에 적합하다. NCM 타입의 양극 활물질을 사용하는 NCM 배터리는 Ni 함유량에 따라 배터리의 용량과 특성이 달라진다. 본 논문에서는 NCM 523, NCM 622, NCM 811 파우치 셀을 사용하여, Ni-Co-Mn의 조성비에 따라 나타나는 특성을 전기화학적 임피던스 분광법(Electrochemical impedance spectroscopy; EIS)을 기반으로 등가 회로 모델(Equivalent circuit model; ECM)의 파라미터를 추출하여 배터리 내부 특성을 비교하고 분석한다.
배터리 팩을 위한 Boost 컨버터 기반 셀 밸런싱 토폴로지 및 스위칭 제어 전략
백인수(Insu Baek),이평연(Pyeongyeon Lee),류승진(Seungjin Ryu),김종훈(Jonghoon Kim) 전력전자학회 2021 전력전자학술대회 논문집 Vol.2021 No.11
배터리 팩을 안전하고 효율적으로 운용하기 위해서는 어플리케이션에서 요구하는 운용 범위에 맞게 출력을 제어할 수 있어야 하며, 운용 중 발생하는 배터리 팩 내부 셀 간 불균형의 최소화가 필요하다. 이의 목적을 달성하기 위해 배터리 팩에 DC/DC 컨버터와 셀 밸런싱 회로 등, 많은 보조 회로를 탑재해야 한다. 본 논문에서는 기존에 셀 밸런싱과는 다르게 셀 간 에너지 교환이 아닌, DC/DC 컨버터의 기능을 수행하면서 셀 밸런싱을 수행하는 Boost 컨버터 기반 셀 밸런싱 토폴로지를 제안한다. PSIM 툴을 사용하여 제안하는 DC/DC 컨버터와 셀 벨런싱 기능을 가진 토폴로지의 성능을 검증한다.